Albert Bourla, Pfizer CEO (Lintao Zhang/Getty Images)
October 10, 2024 11:15 AM EDTUpdated 01:49 PM
People
Pharma

Ex­clu­sive: How an ac­ci­den­tal email tipped Pfiz­er off to an ac­tivist in­vestor’s plan

Drew Armstrong

Executive Editor

Max Bayer

Pharma Reporter

The mes­sage over the week­end to Pfiz­er’s CEO Al­bert Bourla was blank. But it con­tained a warn­ing nonethe­less.

It came from his for­mer CFO Frank …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

A service from the Financial Times